WAT241115P200000
- 0.00
- 0.000.00%
Waters Newsroom
Jefferies Maintains Waters(WAT.US) With Buy Rating, Raises Target Price to $700
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
TD Cowen Maintains Waters(WAT.US) With Hold Rating, Maintains Target Price $410
Wells Fargo Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415
Deutsche Bank Maintains Hold on Waters, Raises Price Target to $325
Waters Corp Price Target Raised to $360.00/Share From $332.00 by Stifel
Waters Corp Is Maintained at Underweight by Barclays
Waters Analyst Ratings
Stifel Nicolaus Remains a Hold on Waters (WAT)
Leerink Partners Adjusts Price Target on Waters to $400 From $375, Maintains Outperform Rating
Wells Fargo Maintains Waters(WAT.US) With Buy Rating, Raises Target Price to $415
Barclays Maintains Waters(WAT.US) With Sell Rating, Raises Target Price to $360
TD Cowen Maintains Waters(WAT.US) With Hold Rating, Raises Target Price to $410
Deutsche Bank Adjusts Price Target on Waters to $325 From $310
Bernstein Adjusts Waters Price Target to $345 From $315, Maintains Market Perform Rating
Barclays Maintains Waters(WAT.US) With Sell Rating, Maintains Target Price $330
Waters Corp Is Maintained at Underweight by Barclays
Waters Analyst Ratings
Barclays Maintains Waters(WAT.US) With Sell Rating, Raises Target Price to $330
Jefferies Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415